Welcome to our dedicated page for Bioquest news (Ticker: BQST), a resource for investors and traders seeking the latest updates and insights on Bioquest stock.
BioQuest Corp. reports company developments centered on its BotMakers conversational AI business. The OTC-traded company completed its acquisition of BotMakers, positioning its public updates around AI-powered voice agents, natural language calling technology, workflow automation, and business outreach tools.
Recurring news for BQST includes customer contracts for outbound AI calling campaigns, executive and technology leadership changes, and the integration of BotMakers as BioQuest's operating focus. Company announcements also describe applications for automated engagement, lead qualification, clinical communication, research workflows, and patient engagement.
BioQuest Corp. (OTC:BQST) through its subsidiary BotMakers has secured a nationwide AI voice calling campaign contract with Atlas Grants. The partnership aims to leverage BotMakers' advanced conversational AI technology to connect Americans with grants, funding opportunities, and nonprofit assistance programs. The company's solution combines natural language voice agents with intelligent workflow automation to scale outreach operations efficiently.
BioQuest (OTC PINK:BQST) has appointed Ed Preble as Chief Technology Officer (CTO), following its recent acquisition of BotMakers, a conversational AI platform. This appointment marks BioQuest's strategic shift from biotechnology to AI automation technology.
Preble brings over 40 years of experience in technology innovation and business growth, with expertise in AI, SaaS, telecom automation, and enterprise infrastructure. He previously served as CEO of Affinity VoIP Telecom and was a professor of eCommerce at San Jose State University.
Following the BotMakers acquisition, BioQuest is expanding its AI-powered solutions including:
- Conversational AI agents for lead engagement
- Omnichannel social media automation
- AI-generated funnels and CRM automations
- Biotech-specific AI solutions for clinical communication
BioQuest (OTC PINK:BQST) has completed its acquisition of BotMakers, a leader in AI-powered conversational technology, and appointed Trent T. Daniel as CEO. The company, trading above $1 per share, previously secured SEC clearance for a $5 million Regulation A offering to fund marketing and platform development.
BotMakers expects to generate revenues exceeding $1.2 million this year, targeting $5 million by end-2026. The company serves notable clients including Infinity Concepts and Colonial Stock Transfer. BotMakers secured a contract with 3Mark Financial for implementing conversational AI technology.
BioQuest plans to rebrand as BotMakers and is negotiating to acquire an AI-powered marketing leads company generating over $1 million in annual revenue. The acquisition strengthens BioQuest's position in enterprise-level AI solutions and automated digital workforce solutions for government, corporate, and law enforcement sectors.